Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway
Open accessAbstract
Background: Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease worldwide. Recent studies have shown that the Angptl2 pathway mediated hepatic inflammatory response plays an important role in the progression of nonalcoholic fatty liver disease. Our study investigated the possible molecular mechanisms of berberine (BBR) in the treatment of the liver inflammatory response in the livers of rats with high-fat diet-induced NAFLD via the Angptl2 pathway. Results: At the end of 12 weeks, compared with the control group rats, the high-fat- diet group rats showed obvious pathological and biochemical changes. The levels of pro-infalmmatory cytokines (CCL2, TNF-α) were increased, the infiltration of inflammatory cells (CCR2) was elevated, and the hepatic mRNA and protein levels of Angptl2, NF-κB and Foxo1 were increased to different degrees. Nevertheless, following treatment with BBR, liver tissue pathology, biochemical data, and Angptl2 pathway-related genes expression were significantly ameliorated. Conclusions: Our findings demonstrate that BBR might attenuate the liver inflammatory response in the livers of rats with high-fat diet-induced NAFLD through the regulation of the Angptl2 pathway.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Berberine has been shown to exhibit other beneficial cardiometabolic effects, including lipid lowering and anti-inflammatory effects.
“Berberine has also been shown to exhibit other beneficial cardiometabolic effects, including lipid lowering and anti-inflammatory effects [144,145].”
From Recent Experimental Studies of Maternal Obesity, Diabetes during Pregnancy and the Developmental Origins of Cardiovascular Disease (2022) · cites this paper as [144]
Maternal administration of natural compounds could also protect offspring from cardiovascular dysfunction through direct effects on the heart or by mitigating GDM-induced obesity or other cardiometabolic conditions.
“Therefore, maternal administration of natural compounds could also protect offspring from cardiovascular dysfunction through direct effects on the heart or by mitigating GDM-induced obesity or other cardiometabolic conditions.”
From Recent Experimental Studies of Maternal Obesity, Diabetes during Pregnancy and the Developmental Origins of Cardiovascular Disease (2022) · cites this paper as [144]
The Methods (Animal experiments; page unavailable) describe berberine treatment in male rats with high-fat-diet-induced fatty liver disease, and the Conclusions concern liver inflammation. Searches for maternal administration, offspring, GDM, and cardiac outcomes found no passage addressing whether natural compounds protect offspring from cardiovascular dysfunction. (LLM, conf=0.78)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · see citing works
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,798 · see citing works
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease
Hotamisligil, G. S. (2010) · Cell · doi:10.1016/j.cell.2010.02.034 · Cited by 2,802 · see citing works
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682 · see citing works
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497 · see citing works
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335c1 · Cited by 1,424 · see citing works
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Perry, R. J., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2014) · Nature · doi:10.1038/nature13478 · Cited by 1,136 · see citing works
Epidemiology of Non-Alcoholic Fatty Liver Disease
Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010) · Digestive Diseases · doi:10.1159/000282080 · Cited by 1,026 · see citing works
Michelotti, G. A., Machado, M. V., & Diehl, A. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.183 · Cited by 974 · see citing works
Turner, N., Li, J.-Y., Gosby, A., To, S. W. C., Cheng, Z., Miyoshi, H., Taketo, M. M., Cooney, G. J., Kraegen, E. W., James, D. E., et al. (2008) · Diabetes · doi:10.2337/db07-1552 · Cited by 535 · see citing works
Epidemiology of non-alcoholic fatty liver disease in China
Fan, J., & Farrell, G. C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.010 · Cited by 501 · see citing works
Tabata, M., Kadomatsu, T., Fukuhara, S., Miyata, K., Ito, Y., Endo, M., Urano, T., Zhu, H. J., Tsukano, H., Tazume, H., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.003 · Cited by 363 · see citing works
Pathology of non‐alcoholic fatty liver disease
Bédossa, P. (2017) · Liver International · doi:10.1111/liv.13301 · Cited by 324 · see citing works
Berberine: a potential phytochemical with multispectrum therapeutic activities
Vuddanda, P. R., Chakraborty, S., & Singh, S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.517745 · Cited by 317 · see citing works
Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis
Valenti, L. V. C., Rametta, R., Dongiovanni, P., Maggioni, M., Fracanzani, A. L., Zappa, M. A., Lattuada, E., Roviaro, G., & Fargion, S. R. (2008) · Diabetes · doi:10.2337/db07-0714 · Cited by 182 · see citing works
FoxO1 Links Insulin Resistance to Proinflammatory Cytokine IL-1β Production in Macrophages
Su, D., Coudriet, G. M., Kim, D. H., Lü, Y., Perdomo, G., Qu, S., Slusher, S., Tse, H. M., Piganelli, J. D., Giannoukakis, N., et al. (2009) · Diabetes · doi:10.2337/db09-0232 · Cited by 180 · see citing works
Chalasani, N., Sanyal, A. J., Kowdley, K. V., Robuck, P. R., Hoofnagle, J. H., Kleiner, D. E., Ünalp, A., & Tonascia, J. A. (2008) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.09.003 · Cited by 166 · see citing works
Diverse roles of ANGPTL2 in physiology and pathophysiology
Kadomatsu, T., Endo, M., Miyata, K., & Oike, Y. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.03.012 · Cited by 160 · see citing works
FOXO animal models reveal a variety of diverse roles for FOXO transcription factors
Arden, K. C. (2008) · Oncogene · doi:10.1038/onc.2008.27 · Cited by 157 · see citing works
Horio, E., Kadomatsu, T., Miyata, K., Arai, Y., Hosokawa, K., Doi, Y., Ninomiya, T., Horiguchi, H., Endo, M., Tabata, M., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.303116 · Cited by 157 · see citing works
Aoi, J., Endo, M., Kadomatsu, T., Miyata, K., Nakano, M., Horiguchi, H., Ogata, A., Odagiri, H., Yano, M., Araki, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1758 · Cited by 132 · see citing works
Chronic Low-Grade Inflammation in Metabolic Disorders: Relevance for Behavioral Symptoms
Lasselin, J., & Capuron, L. (2014) · NeuroImmunoModulation · doi:10.1159/000356535 · Cited by 129 · see citing works
Odagiri, H., Kadomatsu, T., Endo, M., Masuda, T., Morioka, M. S., Fukuhara, S., Miyamoto, T. K., Kobayashi, E., Miyata, K., Aoi, J., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004612 · Cited by 127 · see citing works
Yuan, X., Wang, J., Tang, X., Li, Y., Xia, P., & Gao, X. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0383-6 · Cited by 127 · see citing works
Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases
Motamed, N., Rabiee, B., Poustchi, H., Dehestani, B., Hemasi, G. R., Khonsari, M. R., Maadi, M., Saeedian, F. S., & Zamani, F. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.07.005 · Cited by 100 · see citing works
Xing, L., Zhang, L. R., Liu, T., Hua, Y., Zheng, P., & Ji, G. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.036 · Cited by 88 · see citing works
Zhang, J., Cao, H., Zhang, B., Cao, H., Xu, X., Ruan, H., Yi, T., Tan, L., Qu, R., Song, G., et al. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12119 · Cited by 77 · see citing works
The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease
Zhu, X., Bian, H., & Gao, X. (2016) · Molecules · doi:10.3390/molecules21101336 · Cited by 62 · see citing works
Sasaki, Y., Ohta, M., Dhruv, D., Figueiredo, J., Whelan, M. C., Tomohiro, S., Masaki, Y., Yano, W., Faits, T., Yabusaki, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131176 · Cited by 44 · see citing works
Update on Berberine in Nonalcoholic Fatty Liver Disease
Liu, Y., Zhang, L. R., Song, H., & Ji, G. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/308134 · Cited by 44 · see citing works
Cook, J. R., Matsumoto, M., Banks, A. S., Kitamura, T., Tsuchiya, K., & Accili, D. (2015) · Diabetes · doi:10.2337/db14-1506 · Cited by 34 · see citing works
Sun, Y., Pei, L.-X., Wang, K., et al. (2015) · Molecules · doi:10.3390/molecules21010010 · Cited by 28 · see citing works
Chalasani, N., Younossi, Z. M., Lavine, J. E., et al. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.217 · Cited by 28 · see citing works
Zheng, J., Zou, J., Wang, W., Feng, X., Shi, Y.-Y., Zhao, Y., Jin, G., & Liu, Z. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.04.002 · Cited by 26 · see citing works
Haidarlo, A. J., Rashidbeygi, M., & Ehsanbakhsh, S. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)61297-5 · Cited by 4 · see citing works
Basu, P. P., Shah, N. J., Siriki, R., et al. (2013) · Gastroenterology · doi:10.1016/s0016-5085(13)63754-3 · Cited by 4 · see citing works
Anwar, S., Mushtaq, H., Ullah, N., et al. (2013) · Gut · doi:10.1136/gutjnl-2013-305143.53 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Zhou, H., Ma, C., Wang, C., Gong, L., Zhang, Y., & Li, Y. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173976 · Cited by 73 · see citing works
Ruscica, M., Penson, P. E., Ferri, N., Sirtori, C. R., Pirro, M., Mancini, G. B. J., Sattar, N. A., Toth, P. P., Sahebkar, A., Lavie, C. J., et al. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.06.010 · Cited by 64 · see citing works
Wang, Y., Liu, H., Zheng, M., Yang, Y., Ren, H., Kong, Y., Wang, S., Wang, J., Jiang, Y., Yang, J., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609134 · Cited by 59 · see citing works
Berberine prevents NAFLD and HCC by modulating metabolic disorders.
Lin, X., Zhang, J.-H., Chu, Y., Nie, Q.-Y., & Zhang, J.-M. (2024) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2024.108593 · Cited by 52 · see citing works
Yang, L., Yu, S., Yang, Y., Wu, H., Zhang, X., Lei, Y., & Lei, Z. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116598 · Cited by 43 · see citing works
Chen, P., Li, Y., & Xiao, L. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10543 · Cited by 38 · see citing works
Molecular updates on berberine in liver diseases: Bench to bedside
Bansod, S., Saifi, M. A., & Godugu, C. (2021) · Phytotherapy Research · doi:10.1002/ptr.7181 · Cited by 38 · see citing works
Kereliuk, S. M., & Dolinsky, V. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084467 · Cited by 34 · see citing works
“Berberine has also been shown to exhibit other beneficial cardiometabolic effects, including lipid lowering and anti-inflammatory effects [144,145].”
BackgroundPharmacological properties and therapeutic potential of berberine: a comprehensive review
Fan, K.-Q., Zhang, L., Song, F., Zhang, Y., Chen, T., Cheng, X., Su, N., Zou, Y., Yu, T., Tan, F., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1604071 · Cited by 33 · see citing works
Petrangolini, G., Corti, F., Ronchi, M., Arnoldi, L., Allegrini, P., & Riva, A. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/7563889 · Cited by 29 · see citing works
Sabir, U., Irfan, H. M., Alamgeer, et al. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02234-2 · Cited by 28 · see citing works
AMP‐activated protein kinase is a key regulator of obesity‐associated factors
Mohseni, R., Teimouri, M., Safaei, M., & Sadeghabadi, Z. A. (2022) · Cell Biochemistry and Function · doi:10.1002/cbf.3767 · Cited by 27 · see citing works
Ren, S., Ma, X., Wang, R., Liu, H., Wei, Y., Wei, S., Jing, M., & Zhao, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.742465 · Cited by 26 · see citing works
Bavachin protects against diet-induced hepatic steatosis and obesity in mice
Wei, X., Li, L., Yuan, Q.-Q., Wang, X., Zhang, Q., Zhang, X., Tang, K.-C., Guo, M., Dong, T., Han, W., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01056-z · Cited by 22 · see citing works
Barbhuiya, P. A., Sen, S., & Pathak, M. P. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-023-09912-w · Cited by 19 · see citing works
Radu, F. I., Patoni, C., Nancoff, A.-S., Marin, F.-S., Gaman, L. E., Bucurica, A., Socol, C., Jinga, M., Duţu, M., & Bucurica, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084201 · Cited by 19 · see citing works
Guo, Q., Wang, C., Xue, X., et al. (2021) · BioMed Research International · doi:10.1155/2021/9311855 · Cited by 19 · see citing works
Ganegamage, S. K., & Heagy, M. D. (2022) · Current Organic Chemistry · doi:10.2174/1385272826666220811102939 · Cited by 17 · see citing works
Role of the angiopoietin-like protein family in the progression of NAFLD
Su, X., Xu, Q., Li, Z., Ren, Y., Jiao, Q., Wang, L., & Wang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27739 · Cited by 18 · see citing works
Hepatocellular Interactions of Potential Nutraceuticals in the Management of Inflammatory NAFLD
Ezhilarasan, D., & Kulanthaivel, L. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4112 · Cited by 17 · see citing works
Pan, L., Feng, R., Hu, J., Yu, H., Tong, Q., Yang, X., Song, J., Xu, H. X., Ye, M., Zhang, Z., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.08.009 · Cited by 15 · see citing works
Gupta, P., Rawal, S., Bhatnagar, P., Yadav, H. N., & Dinda, A. K. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220617113744 · Cited by 15 · see citing works
Cervello, M., Augello, G., Cocco, L., Ratti, S., Follo, M. Y., Martelli, A. M., Cusimano, A., Montalto, G., & McCubrey, J. A. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101032 · Cited by 9 · see citing works
Ma, C., Wang, C., Zhang, Y., Zhou, H., & Li, Y. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467215666211217120448 · Cited by 9 · see citing works
Jiang, S.-T., Liu, Y., Zhang, L., Sang, X., Xu, Y.-Y., & Lu, X. (2022) · European Journal of Medical Research · doi:10.1186/s40001-022-00865-y · Cited by 8 · see citing works
Sharma, S., Kaur, I., Dubey, N., Goswami, N., & Tanwar, S. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05054-6 · Cited by 8 · see citing works
Effects of Berberine on Leukemia with a Focus on Its Molecular Targets
Mazandaranian, M. R., Dana, P. M., Asemi, Z., et al. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220324092302 · Cited by 7 · see citing works
LCN2 contributes to the improvement of nonalcoholic steatohepatitis by 8-Cetylberberine
He, H., Chai, X., Li, J., Li, C., Wu, X., Ye, X., Ma, H., & Li, X. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121595 · Cited by 6 · see citing works
Lotfy, M. A., Abdel-Kawi, S. H., Mohamed, D., & mogahed, O. (2023) · The Egyptian Journal of Histology · doi:10.21608/ejh.2023.181583.1835 · Cited by 5 · see citing works
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Valle-Velázquez, E., Cabrera-Angeles, J. C., Sánchez-Gloria, J. L., Sánchez‐Muñoz, F., Arellano-Buendía, A. S., Sánchez‐Lozada, L. G., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123638 · Cited by 4 · see citing works
Zhao, X., Xia, F., Dong, Z., Huang, W., Kong, X., Cui, Z., Yan, M., Gao, H., Rong, R., Wang, M., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156823 · Cited by 3 · see citing works
Self-citationKarimi, A., Vajdi, M., Sanaie, S., Akhlaghi, S., Negari, A., Dashti, F., & Azar, P. S. (2023) · Journal of Food Biochemistry · doi:10.1155/2023/7277060 · Cited by 3 · see citing works
Tree Turmeric: A Super Food and Contemporary Nutraceutical of 21st Century – A Laconic Review
Bhasin, J. K., Thakur, B., Kumar, S., et al. (2021) · Journal of the American Nutrition Association · doi:10.1080/07315724.2021.1958104 · Cited by 3 · see citing works
Zhu, W., Yang, L., Dai, Y., Wang, H., Zhou, J., Xia, L., & Shen, T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1460643 · Cited by 2 · see citing works
Serum ANGPTL2 and ANGPTL3 as potential biomarkers for diagnosis of non-alcoholic fatty liver disease
Yang, L., Zhao, D., Ma, Y., Wang, Y., Zhang, Q., & Lang, J. (2020) · Environmental Disease · doi:10.4103/ed.ed_33_19 · Cited by 2 · see citing works
Martínez, G., & Ángel, M. (2012) · Congreso de los Diputados eBooks · Cited by 2 · see citing works
Chen, J., Huang, Y., Chen, H., Yang, Q., Zheng, W., Lin, Y., Xue, M., & Wang, C. (2024) · Human Mutation · doi:10.1155/2024/5573272 · Cited by 1 · see citing works
Eskandrani, A. A., Khater, S. I., El-Emam, M. M. A., et al. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103355 · Cited by 1 · see citing works
Fatty liver disease: Functional foods offer natural remedies
Zhao, M., Yi, Z., Zhang, B., Chen, S., Zhuang, X., Yin, H., & Zhao, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91747-6.00001-9 · Cited by 1 · see citing works
Cooperative game theoretical approaches to negotiation and group decision
Kıbrıs, Ö. (2008) · Sabanci University · Cited by 1 · see citing works
Alam, S. B., Kulka, M., & Wang, Y. (2023) · Preprints.org · doi:10.20944/preprints202302.0238.v1 · Cited by 1 · see citing works
He, H., Wu, S., & Yi, J. (2026) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x26500643
Yu, F., Yin, S., Jiayu, Z., & Sun, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1969017
- Authors
- Lu, Z., He, B., Chen, Z., Yan, M., & Wu, L.
- Affiliations
- Tongde Hospital of Zhejiang Province (CN)
- Corresponding author
- Wu, Liyan
- Venue
- BMC Immunology
- Published
- 2020-05-19
- Volume
- 21
- Issue
- 1
- Pages
- 28-28
- ISSN
- 1471-2172 (ISSN-L)
- PMC
- PMC7236478
- OpenAlex
- W3027002103
- Semantic Scholar
- 45d526ceb5f9f57622fe88de20274789ee335401
- Cited by
- 43
- References
- 39
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 1 · 2012: 1
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- BMC Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Chinese Medicine Research Program of Zhejiang Province (2016ZB004, 2019ZA024)
- the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2018KY322)
- the Program of Zhejiang Province Natural Science Foundation (LY17H290007)
- Topics
- Health Sciences › Medicine › Pharmacology › Berberine and alkaloids research
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- berberine, non-alcoholic fatty liver disease, ANGPTL2, liver inflammation, NF-κB, FOXO1, high-fat diet, inflammatory cytokines, TNF-α, MCP-1, CCR2, anti-inflammatory activity
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 2, Animals, Anti-Inflammatory Agents, Berberine, Inflammation, Liver, Male, RNA, Messenger, Signal Transduction, NF-kappa B, Rats, Sprague-Dawley, Rats, Diet, High-Fat, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
